Welcome : Guest

Press Release


MCP-1093: AUTOMATED AND RAPID MICROBIOLOGICAL TESTS – A GLOBAL STRATEGIC BUSINESS REPORT

January 10, 2017 – Non-Clinical Applications to Drive the Automated and Rapid Microbiological Tests Market, According to a New Report by Global Industry Analysts, Inc.

GIA launches comprehensive analysis of industry segments, trends, growth drivers, market share, size and demand forecasts on the global Automated and Rapid Microbiological Tests market. The global market for Automated and Rapid Microbiological Tests is forecast to reach US$6.5 billion by 2022, driven by the increasing penetration of laboratory automation and rapid tests in non-clinical applications.

Non-clinical applications have emerged as a major market for automated and rapid microbiological tests, owing to impetus from regulatory authorities for safety of processed food. Non-clinical applications are gaining share from clinical applications and currently account for over 50% of revenues generated in the market. In the healthcare end-use sector, rapid pathogen identification and analysis is gaining in importance due to the increase in outbreak of new diseases caused by mutant microorganisms, as well as new pathogens. Rapid and reliable detection of pathogenic bacteria is critical in preventing disease progression and spread. As a result, the growing need to speed up microbiological testing is driving demand for automated and rapid microbiological tests. Another key factor driving growth in the market is the growing focus on quality of healthcare services as major reforms push healthcare into a more value driven system. The need to enhance the accuracy and efficiency of medical treatment decision will therefore continue to drive demand for automated and rapid microbiological tests. Increased use of automated and rapid microbiological tests in the healthcare system will help provide quicker disease management, enable administration of appropriate antimicrobial therapy, and reduce morbidity and mortality rates while simultaneously lowering associated costs.

The market also stands to benefit from the recent advances in DNA probes, monoclonal antibodies, biochips, immunoassays, specimen collection devices, new detection technologies, computers and automation that have permitted the development of versatile and reliable diagnostics. Advanced microbiological procedures not only promise to provide results with the same accuracy as that of the conventional tests, but also significantly enhance sensitivity and specificity of the procedure. With increasing competition, manufacturers are focusing on the development of new, innovative, affordable and easy-to-use tests. Strong growth in the global point-of-care market is additionally driving market opportunities for the use of automated and rapid microbiological tests.

As stated by the new market research report on Automated and Rapid Microbiological Tests, the United States represents the largest market worldwide supported by a well- developed healthcare industry and the strong emphasis on early diagnosis and treatment. Asia-Pacific is forecast to spearhead global growth with a CAGR of 8.8% over the analysis period led by growing population and a parallel increase in healthcare burden, rising healthcare awareness and spending as a result of growing affluence and health literacy, rise of Asian countries as major food exporters and the resulting need to conform to stringent international food safety standards. Automated Identification and Susceptibility Systems represents the largest market segment, while Non-Clinical Applications represent the fastest growing segment.

Major players covered in the report include Abbott Laboratories, Abbott Molecular, Inc., Alere Inc, Becton Dickinson and Company, bioMérieux SA, bioMerieux, Inc., Bio-Rad Laboratories, Inc, Cellabs Pty Ltd., CorisBioconcept SPRL, F. Hoffmann-La Roche AG, Hologic, Inc., MedMira Inc., Meridian Bioscience, Inc., OraSure Technologies, Inc., Orion Diagnostica Oy, Quidel Corporation, Sekisui Diagnostics, LLC, Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., and Oxoid Limited, among others.

The research report titled "Automated and Rapid Microbiological Tests: A Global Strategic Business Report" announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, growth drivers, regulations, issues, market challenges, mergers and acquisitions, regulatory approvals, and other strategic industry activities of major and niche players worldwide. The report provides market estimates and projections in dollars for all major geographic markets, including the US, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, Russia and Rest of Europe), Asia-Pacific (China, India and Rest of Asia-Pacific), Latin America (Brazil and Rest of Latin America), and Rest of World. End-Use Applications analyzed include Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications.

 

» View Complete Report Details

« Back